000178590 001__ 178590
000178590 005__ 20240229143550.0
000178590 0247_ $$2doi$$a10.14309/ctg.0000000000000458
000178590 0247_ $$2pmid$$apmid:35060941
000178590 0247_ $$2altmetric$$aaltmetric:121385210
000178590 037__ $$aDKFZ-2022-00139
000178590 041__ $$aEnglish
000178590 082__ $$a610
000178590 1001_ $$0P:(DE-He78)20dc4ad11ff465acf5b99f1e679e10b7$$aNiedermaier, Tobias$$b0$$eFirst author$$udkfz
000178590 245__ $$aVariation of positive predictive values of fecal immunochemical tests by polygenic risk score in a large screening cohort.
000178590 260__ $$aLondon$$bNature Publ. Group$$c2022
000178590 3367_ $$2DRIVER$$aarticle
000178590 3367_ $$2DataCite$$aOutput Types/Journal article
000178590 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1651150675_30565
000178590 3367_ $$2BibTeX$$aARTICLE
000178590 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000178590 3367_ $$00$$2EndNote$$aJournal Article
000178590 500__ $$a#EA:C070#LA:C070#LA:C120# / 2022 Jan 19;13(3):e00458
000178590 520__ $$aPrevalence of colorectal neoplasms varies by polygenic risk scores (PRS). We aimed to assess to what extent PRS might be relevant for defining personalized cutoff values for fecal immunochemical tests (FITs) in colorectal cancer (CRC) screening.Among 5,306 participants of screening colonoscopy who provided a stool sample for a quantitative FIT (Ridascreen Hemoglobin or FOB Gold) prior to colonoscopy a PRS was determined, based on the number of risk alleles in 140 , single nucleotide polymorphism. Subjects were classified into low, medium and high genetic risk for colorectal neoplasms according to PRS tertiles. We calculated positive predictive values (PPVs) and numbers needed to scope (NNS) to detect one advanced neoplasm (AN) by risk group, and cutoff variation needed to achieve comparable PPVs across risk groups in the samples tested with Ridascreen (N=1,271) and FOB Gold (N=4,035) independently, using cutoffs yielding 85%, 90% or 95% specificity.Performance of both FITs was very similar within each PRS group. For a given cutoff, PPVs were consistently higher by 11%-15% units in the high-risk PRS group compared to the low-risk group (all P-values <0.05). Correspondingly, numbers needed to scope (NNS) to detect one advanced neoplasm varied from 2 (high PRS, high cutoff) to 5 (low PRS, low cutoff). Conversely, very different FIT cutoffs would be needed to ensure comparable PPVs across PRS groups.PPVs and NNS of FITs varied widely across people with high and low genetic risk score. Further research should evaluate the relevance of these differences for personalized CRC screening.This study was partly funded by grants from the German Research Council (DFG, grant No. BR1704/16-1), the Federal Ministry of Education and Research (BMBF, grant no. 01GL1712), and the German Cancer Aid (No. 70113330).
000178590 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000178590 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
000178590 7001_ $$0P:(DE-HGF)0$$aBalavarca, Yesilda$$b1
000178590 7001_ $$0P:(DE-He78)6d4d6a0e2d726f899086ca98cd560922$$aGies, Anton$$b2$$udkfz
000178590 7001_ $$0P:(DE-He78)f4e98340e600f7411886c21c7b778d36$$aWeigl, Korbinian$$b3$$udkfz
000178590 7001_ $$0P:(DE-He78)0311ebf3415e41860b4e2c56fbae6919$$aGuo, Feng$$b4$$udkfz
000178590 7001_ $$0P:(DE-He78)9b2a61b2abe4a64ca23b6783b7c4fe63$$aAlwers, Elizabeth$$b5$$udkfz
000178590 7001_ $$0P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f$$aHoffmeister, Michael$$b6$$udkfz
000178590 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b7$$eLast author$$udkfz
000178590 773__ $$0PERI:(DE-600)2581516-7$$a10.14309/ctg.0000000000000458$$gVol. Publish Ahead of Print$$n3$$pe00458$$tClinical and translational gastroenterology$$v13$$x2155-384X$$y2022
000178590 909CO $$ooai:inrepo02.dkfz.de:178590$$pVDB
000178590 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)20dc4ad11ff465acf5b99f1e679e10b7$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000178590 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000178590 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6d4d6a0e2d726f899086ca98cd560922$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000178590 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f4e98340e600f7411886c21c7b778d36$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000178590 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)0311ebf3415e41860b4e2c56fbae6919$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000178590 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)9b2a61b2abe4a64ca23b6783b7c4fe63$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000178590 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000178590 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000178590 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000178590 9141_ $$y2022
000178590 915__ $$0LIC:(DE-HGF)CCBYNCNDNV$$2V:(DE-HGF)$$aCreative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND (No Version)$$bDOAJ$$d2021-01-29
000178590 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-29
000178590 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-29
000178590 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2021-01-29
000178590 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2021-01-29
000178590 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCLIN TRANSL GASTROEN : 2021$$d2022-11-12
000178590 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-12
000178590 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-12
000178590 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2019-08-29T13:10:21Z
000178590 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2019-08-29T13:10:21Z
000178590 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2019-08-29T13:10:21Z
000178590 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-12
000178590 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-12
000178590 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2022-11-12
000178590 9202_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000178590 9202_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x1
000178590 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000178590 9201_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x1
000178590 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x2
000178590 9200_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000178590 980__ $$ajournal
000178590 980__ $$aVDB
000178590 980__ $$aI:(DE-He78)C070-20160331
000178590 980__ $$aI:(DE-He78)C120-20160331
000178590 980__ $$aI:(DE-He78)HD01-20160331
000178590 980__ $$aUNRESTRICTED